Physician profile
Aaron David
NPI 1932263514
$639.13
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $157 · 2021: $67.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $153.63 | 2019 | |
| Exeltis, USA INC. | $93.47 | 2019-2020 | |
| Amarin Pharma, INC. | $77.46 | 2019-2021 | |
| Duchesnay USA Incorporated | $60.52 | 2019 | |
| Lupin INC. | $58.35 | 2020-2021 | |
| Millicent US INC | $35.94 | 2020 | |
| Aspira Women'S Health INC | $32.60 | 2019-2021 | |
| Daiichi Sankyo INC. | $31.54 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $29.82 | 2019 | |
| Mission Pharmacal Company | $27.42 | 2019 | |
| Novum Pharma, LLC | $25.25 | 2019 | |
| Therapeuticsmd, INC. | $13.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.